A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.

@article{Vardas2010AP2,
  title={A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.},
  author={Eftyhia Vardas and Pontiano Kaleebu and Linda-Gail Bekker and Anwar Hoosen and Elwyn Nachanya Chomba and Philip R. Johnson and Pervin Anklesaria and Josephine Birungi and Burc Barin and Mark Boaz and Josephine H. Cox and Jennifer K Lehrman and Gwynn Stevens and J. K. Gilmour and Tony Tarragona and Peter F. Hayes and Sarah Lowenbein and Eva Kizito and Patricia Fast and Alison E. Heald and Claudia L. Schmidt},
  journal={AIDS research and human retroviruses},
  year={2010},
  volume={26 8},
  pages={933-42}
}
The recombinant vaccine, tgAAC09, based on an adeno-associated virus serotype 2 (AAV2) vector encoding HIV-1 subtype C Gag, protease, and part of reverse transcriptase, induced robust T cell and antibody responses in nonhuman primates. In a previous phase I study in 80 healthy HIV-seronegative European and Indian adults, the vaccine was generally safe, well tolerated, and modestly immunogenic when administered once at doses up to 3 x 10(11) DRP. This phase II double-blind, randomized, placebo… CONTINUE READING